Abstract
Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have